Calcium Channel Blockers as Tocolytics Principles of Their Actions, Adverse Effects and Therapeutic Combinations /
Dihydropyridine Ca 2+ channel blockers (CCBs) are widely accepted in the treatment of premature labour. Their mechanism of action in tocolysis involves the blockade of L-type Ca 2+ channels, influenced by the Ca 2+ -activated K + channels, beta-adrenergic receptors (β-ARs) and sexual hormones. In...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2013
|
| Sorozat: | PHARMACEUTICALS
6 No. 6 |
| doi: | 10.3390/ph6060689. |
| mtmt: | 2322286 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/16143 |
| LEADER | 02267nab a2200217 i 4500 | ||
|---|---|---|---|
| 001 | publ16143 | ||
| 005 | 20190719100801.0 | ||
| 008 | 190719s2013 hu o 0|| zxx d | ||
| 022 | |a 1424-8247 | ||
| 024 | 7 | |a 10.3390/ph6060689. |2 doi | |
| 024 | 7 | |a 2322286 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Gáspár Róbert | |
| 245 | 1 | 0 | |a Calcium Channel Blockers as Tocolytics |h [elektronikus dokumentum] : |b Principles of Their Actions, Adverse Effects and Therapeutic Combinations / |c Gáspár Róbert |
| 260 | |c 2013 | ||
| 300 | |a 689-699 | ||
| 490 | 0 | |a PHARMACEUTICALS |v 6 No. 6 | |
| 520 | 3 | |a Dihydropyridine Ca 2+ channel blockers (CCBs) are widely accepted in the treatment of premature labour. Their mechanism of action in tocolysis involves the blockade of L-type Ca 2+ channels, influenced by the Ca 2+ -activated K + channels, beta-adrenergic receptors (β-ARs) and sexual hormones. In clinical practice, most experience has been gained with the use of nifedipine, whose efficacy is superior or comparable to those of β-agonists and oxytocin antagonists. Additionally, it has a favourable adverse effect profile as compared with the majority of other tocolytics. The most frequent and well-tolerated side-effects of CCBs are tachycardia, headache and hypotension. In tocolytic therapy efforts are currently being made to find combinations of tocolytic agents that yield better therapeutic action. The available human and animal studies suggest that the combination of CCBs with β-AR agonists is beneficial, although such combinations can pose risk of pulmonary oedema in multiple pregnancies and maternal cardiovascular diseases. Preclinical data indicate the potential benefit of combinations of CCBs and oxytocin antagonists. However, the combinations of CCBs with progesterone or cyclooxygenase inhibitors may decrease their efficacy. The CCBs are likely to remain one of the most important groups of drugs for the rapid inhibition of premature uterine contractions. Their significance may be magnified by further clinical studies on their combined use for tocolysis. | |
| 700 | 0 | 2 | |a Hajagos-Tóth Judit |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/16143/1/GasparRpharmaceuticals2013.pdf |z Dokumentum-elérés |